tyb
Merck to offer Ebola vaccine at lowest price for poor nations
Merck & Co. said Friday it expects to make licensed doses of its recently approved Ebola vaccine available in the third quarter of 2020 and price the single-dose injection at the lowest possible access price for poor and middle-income countries. The vaccine, Ervebo, was approved by the U.S. Food and Drug Administration on Thursday, a month after Europe gave its nod to the vaccine, a move that has been hailed by the World Health Organization. “We have made a commitment to making the vaccine available to GAVI-eligible countries at the lowest possible access price,” Merck spokesman Skip Irvine said. “We have made that commitment, but we have not yet established the price for the vaccine.”
Stockpile of 500,000 doses of Ebola vaccine is being established for emergency use in outbreaks of the deadly fever by the GAVI global vaccine alliance, Reuters reported earlier this month. The stockpiling will start with Merck’s Ervebo vaccine. GAVI, a public-private partnership backed by the Bill & Melinda Gates Foundation, the WHO, the World Bank and UNICEF, arranges bulk buys to reduce vaccine costs for poor countries. “We are partnering with both GAVI and WHO to put that stockpile in place as quickly as possible,” the company said in a statement, adding that the stockpile of vaccines will be governed and executed by the owner of the stockpile and not by Merck.
There have been more than 3,000 cases of Ebola, including 2,199 deaths, in the outbreak that was declared in August 2018.
https://the-japan-news.com/news/article/0006247627?fp=5db946146cb714aaca68ee9d56489b28
>should anon be surprised?
no. Nothing should really surprise you at this point. Amuse you or a "well did not expect that much" sure. Surprise? no.
Top Insider Sale/Buy of the week: Uber, Inc former CEO founder: $383.31m- Dec 16-18 and Neoleukin Therapeutics bought by Baker Bro's Advisors LLC: $25.34m-Dec 20
Uber’s Ex-CEO Travis Kalanick Has Dumped 90% Of His Stock In Just Six Weeks
Travis Kalanick’s selling streak continues: His Uber stock sales have crossed the $2.5 billion mark. The former CEO of the ride-hailing company has sold off over 90% of his stake, nearly 90 million shares, since November 6 when Uber’s lock-up expired, giving executives and board members their first chance to sell.
In the past six weeks, Kalanick has sold around $2.5 billion in stock, including a $600 million chunk held by his charitable remainder trust. Forbes estimates Kalanick’s net worth to be around $2.7 billion, down from $3.5 billion in early October for The Forbes 400 list. The majority of his wealth now sits in assets that are not Uber shares. Forbes does not count charitable remainder trusts as part of a billionaire’s net worth since such trusts are earmarked for charitable giving.
https://www.forbes.com/sites/bizcarson/2019/12/18/uber-travis-kalanick-sells-most-of-his-shares/#44753993451f
Neoleukin Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
Neoleukin Therapeutics, Inc. (“Neoleukin”) (Nasdaq: NLTX), a bio-pharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced the closing of its public offering of 10,263,750 shares of its common stock at a public offering price of $8.40 per share, which includes the exercise in full of the underwriters’ option to purchase 1,338,750 shares of common stock.The aggregate gross proceeds to Neoleukin, before deducting underwriting discounts and commissions and estimated offering expenses payable by Neoleukin, were approximately $86.2 million.
BofA Securities, Piper Jaffray and Guggenheim Securities acted as joint book-running managers for the offering. Canaccord Genuity acted as lead manager for the offering.
The securities were offered by Neoleukin pursuant to a registration statement on Form S-3 previously filed and declared effective by the Securities and Exchange Commission (SEC).
https://www.globenewswire.com/news-release/2019/12/20/1963742/0/en/Neoleukin-Therapeutics-Announces-Closing-of-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html
Neoleukin Therapeutics, Inc
Neoleukin Therapeutics, Inc., formerly Aquinox Pharmaceuticals, Inc., is a biopharmaceutical company. The Company is focused on the development and commercialization of computationally-designed protein therapeutics to address unmet medical needs in immuno-oncology, inflammation, and autoimmunity. Its computational platform allows it to design new de novo proteins to treat serious diseases, including cancer, inflammatory, and autoimmune disorders. Its lead program, NL-201, is a computationally-designed de novo protein therapeutic. NL-201 is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. NL-201 is designed for use as a single-agent or in combination with complementary therapeutic modalities.
Number of employees : 8 people.
https://www.finviz.com/insidertrading.ashx?oc=1732125&tc=2&b=2
https://www.finviz.com/insidertrading.ashx?oc=1263508&tc=1&b=2
the economy will not tank as in years past. You cannot allow the same cycle of boom/bust which allows the system to buy it back cheaper and ride it up again.
See this
Napoleon Escapes and Rothschild Makes a Killing
https://www.mindcontagion.org/banking/hb1815.html
this can't habben again or it will kick the can.
Not all debt will be cancelled or zeroed out ala the Walter Sobchek method. Some of it will.
Timing? After the next election and closer to end of second term.
42cd09 (33)
have fun talkin' to yourself nb
and knowing your type you'll be a YUGE faggot and bring it into the nb